Home Blog Page 3
DNA Test Sanger Sequencing
Leveraging improvements in sequencing technology that increase speed and lower costs, rare disease diagnostics broadens its reach.
DNA Capsules
Pharmacogenomic testing is gaining traction, but incorporating it into the clinical setting with high fidelity requires a delicate balance.
These cramps are getting worse now
Two independent sets of research published in Science Immunology have demonstrated how a subset of immune cells in the gut, known as group 3 innate lymphoid cells (ILC3), are tuned to the body’s daily circadian clock as they sense and interact with gut microbes. Collective results from the research indicate that specific “clock genes” that are expressed in synchrony...
Verge Genomics has raised $32 million in Series A financing toward further development of new treatments by combining machine learning and neuroscience with experimental biology. [Source: kentoh/Getty Images]
Novartis will establish an “AI innovation lab” designed to enable its research and commercial employees to use Microsoft’s artificial intelligence solutions across operations, with the aim of transforming how new treatments are discovered, developed, and commercialized. The pharma giant has selected Microsoft as its partner for a multi-year AI-based R&D effort, through a collaboration whose value was not disclosed. The...
Cepheid announced that it has received clearance from the FDA for its Xpert BCR-ABL Ultra for monitoring disease burden in patients with chronic myeloid leukemia (CML). An important aspects of managing CML is regular and frequent monitoring of a patient's response to therapy by measuring BCR-ABL gene transcript levels as an indicator of treatment efficacy and as a predictor of...
Two new reference data sources, Mastermind and DECIPHER, are being added to Congenica’s clinical decision support platform for genomic data interpretation.  Genomenon’s Mastermind, which is used by hundreds of genetic labs worldwide, has indexed nearly 7 million full text articles and 500,000 supplemental data sets and covers over 4.9 million variants found in the medical literature. DECIPHER contains disease-causing...
Berg will partner with Massachusetts General Hospital and Brigham and Women's Hospital to study potential biomarkers for Alzheimer's and other neurodegenerative disorders from Harvard Biomarker Study biospecimens. [Source: ajcity.net]
The National Institute on Aging (NIA) has committed an estimated $73 million over the next five years to “diversify and reinvigorate the Alzheimer’s disease drug development pipeline,” according to an NIH press release. Two new Alzheimer Centers for the Discovery of New Medicines are receiving the funding. The two centers, which are multi-institutional, are: The Open Drug Discovery Center...
September / October 2019 Read Magazine Now
Medical vaccine
Scientists at Arizona State University’s Biodesign Institute now report on the identification of more than 200,000 cancer neoantigens, which could feasibly lead to the development of broad-spectrum cancer vaccines, as well as tumor type-specific treatments or patient-personalized vaccines. “In a cancer cell, it turns out that all levels of information transfer from DNA to RNA to protein become more...
Dana-Farber Cancer Institute researchers report the development of a new blood test that has shown the ability in a multi-center trial to screen for numerous types of cancer with a high degree of accuracy. The team discussed the novel test and presented the results of the trial during a recent session at the European Society for Medical Oncology (ESMO)...
Scroll Up